Thomas M. Grogan - Concepedia

Author

Thomas M. Grogan

Also Known As

T Grogan, T M Grogan, T. Grogan, T. M. Grogan, T.M. GROGAN, T.M. Grogan, THOMAS M. GROGAN, Thomas Grogan, Thomas M Grogan, Thomas M. Grogan

224

Publications

25.4K

Citations

H-Index

116

Concepts

All Affiliations

University of Arizona Ventana Research Corporation (United States)University of Würzburg Universitat de Barcelona National Cancer Institute

About

Thomas M. Grogan is an author at University of Arizona specializing in medicine, pathology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	56	7.6K
2	Health Sciences	8	8	1.2K
3	Engineering	3	3	157
4	Natural Sciences	1	1	28
5	Biochemistry	1	1	31

Thomas M. Grogan

126

Publications

22.4K

Citations

H-Index

Page 1

	Year	Citations
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma Andreas Rosenwald, George W. Wright, Wing C. Chan, New England Journal of Medicine	2002	3.8K
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells Sandeep S. Davé, George W. Wright, Bruce K. Tan, New England Journal of Medicine	2004	1.4K
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma Andreas Rosenwald, George W. Wright, Karen Leroy, The Journal of Experimental Medicine Molecular DiagnosisImmunologyPathologyImmunotherapyHematological Malignancy	2003	1.1K
Chemotherapy Alone Compared with Chemotherapy plus Radiotherapy for Localized Intermediate- and High-Grade Non-Hodgkin's Lymphoma Thomas P. Miller, Steve Dahlberg, J. Robert Cassady, New England Journal of Medicine	1998	1K
Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Nathalie A. Johnson, Graham W. Slack, Kerry J. Savage, Journal of Clinical Oncology	2012	954
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma Andreas Rosenwald, George W. Wright, Adrian Wiestner, Cancer Cell Lymphoid NeoplasiaMantle Cell LymphomaOncogenic AgentQuantitative IntegratorPathology	2003	924
Molecular Diagnosis of Burkitt's Lymphoma Sandeep S. Davé, Kai Fu, George W. Wright, New England Journal of Medicine	2006	902
Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases Stefano Pileri, Thomas M. Grogan, Nancy L. Harris, Histopathology	2002	662
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. William S. Dalton, Thomas M. Grogan, Paul S. Meltzer, Journal of Clinical Oncology ImmunologyContinuous Infusion VerapamilPathologyPharmacotherapyImmunotherapy	1989	560
Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. William Bellamy, L Richter, Y Frutiger, PubMed Hematopoietic MalignanciesHuman VegfAngiogenesisVegf MessageImmunology	1999	531

Page 1